NDAINTRAVENOUSPOWDER
Approved
Aug 2018
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
5/8 — Partial
TIGECYCLINE (tigecycline) by Accord Biopharma. Approved for community-acquired bacterial pneumonia, complicated intra-abdominal infection, complicated skin and skin structure infection. First approved in 2018.
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Tigecycline is a broad-spectrum intravenous tetracycline-class antibiotic approved in 2018 for treatment of complicated bacterial infections including pneumonia, intra-abdominal infections, and skin/soft tissue infections. It is effective against both gram-positive and gram-negative bacteria, including carbapenem-resistant organisms and Mycobacterium abscessus. The drug works by inhibiting bacterial protein synthesis through tetracycline-class mechanisms.
$597KPart D
Peak6.9 years to LOETigecycline is in peak lifecycle with minimal Part D spending, suggesting narrow market penetration within IV antibiotic specialty care with a small commercial team.
Mechanism of Action
Pharmacologic Class:
Tetracycline-class Antibacterial
Worked on TIGECYCLINE at Accord Biopharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.